For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologically or cytologically confirmed previously treated metastatic colorectal
             cancer with adenocarcinoma histology and in Stage IV per American Joint Committee on
             Cancer (version 4.0) at study entry

          -  Microsatellite status should be performed per local standard of practice,
             immunohistochemistry (IHC) and/or PCR. If IHC results are equivocal, PCR is required
             for determining microsatellite stable (MSS) status

          -  Must have measurable disease per RECIST 1.1. Participants with lesions in a previously
             irradiated field as the sole site of measurable disease will be permitted to enroll
             provided the lesion(s) have demonstrated clear progression and can be measured
             accurately

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 at screening and
             on cycle 1 day 1 (C1D1)

        Exclusion Criteria:

          -  BRAF V600 mutant colorectal cancer

          -  Active brain metastases or leptomeningeal metastases

          -  Active, known or suspected autoimmune disease

          -  Participants with a condition requiring systemic treatment with either corticosteroids
             (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within
             14 days of study treatment administration

          -  History of interstitial lung disease or pneumonitis

          -  Prior treatment with immune checkpoint inhibitors and mitogen-activated protein kinase
             enzymes (MEK) inhibitors

          -  History of allergy or hypersensitivity to study drug components

        Other protocol defined inclusion/exclusion criteria apply